Trulicity 0.75 mg, solution injectable stylo pré-remplie à usage unique

( ARTG ) Type 2 Diabetes Mellitus: glycaemic control,TRULICITY is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:, As monotherapy., In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 5.1 for data with respect to different combinations),Type 2 Diabetes Mellitus: reduction in risk of major adverse cardiovascular events,TRULICITY is indicated as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have:, established cardiovascular disease or, multiple cardiovascular risk factors